H Kim1, K-J Park1, B-K Ryu1, D-H Park1, D-S Kong2, K Chong1, Y-S Chae3, Y-G Chung1, S I Park4,5,6,7, S-H Kang1. 1. Department of Neurosurgery, Korea University Anam Hospital, Seoul, Korea. 2. Department of Neurosurgery, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea. 3. Department of Pathology, Korea University College of Medicine, Seoul, Korea. 4. Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul, Korea. 5. The BK21 Plus Program, Korea University College of Medicine, Seoul, Korea. 6. Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. 7. Vanderbilt Centre for Bone Biology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Abstract
AIMS: Aggressive meningioma remains incurable with neither chemo- nor targeted therapies proven effective, largely due to unidentified genetic alterations and/or aberrant oncogenic pathways driving the disease progression. In this study, we examined the expression and function of Forkhead box M1 (FOXM1) transcription factor during meningioma progression. METHODS: Human meningioma samples (n = 101) were collected, followed by Western blotting, quantitative PCR, immunohistochemical and progression-free survival (PFS) analyses. For in vitro assays, FOXM1 was overexpressed or knocked-down in benign (SF4433 and SF4068) or malignant (SF3061 and IOMM-Lee) human meningioma cell lines respectively. For in vivo studies, siomycin A (a FOXM1 inhibitor)-pretreated or control IOMM-Lee cells were implanted subcutaneously in nude mice. RESULTS: FOXM1 expression was increased in higher grades of meningioma and correlated with the mitotic index in the tumour tissue. Moreover, FOXM1 was increased in recurrent meningioma compared with the matched primary lesions. The patients who had higher FOXM1 expression had shorter PFS. In the subsequent in vitro assays, knockdown of FOXM1 in malignant meningioma cell lines resulted in decreased tumour cell proliferation, angiogenesis and invasion, potentially via regulation of β-catenin, cyclin D1, p21, interleukin-8, vascular endothelial growth factor-A, PLAU, and epithelial-to-mesenchymal transition-related genes, whereas overexpression of FOXM1 in benign meningioma cell lines had the opposite effects. Last, suppression of FOXM1 using a pharmacological inhibitor, siomycin A, decreased tumour growth in an in vivo mouse model. CONCLUSIONS: Our data demonstrate that FOXM1 is a key transcription factor regulating oncogenic signalling pathways in meningioma progression, and a promising therapeutic target for aggressive meningioma.
AIMS: Aggressive meningioma remains incurable with neither chemo- nor targeted therapies proven effective, largely due to unidentified genetic alterations and/or aberrant oncogenic pathways driving the disease progression. In this study, we examined the expression and function of Forkhead box M1 (FOXM1) transcription factor during meningioma progression. METHODS:Humanmeningioma samples (n = 101) were collected, followed by Western blotting, quantitative PCR, immunohistochemical and progression-free survival (PFS) analyses. For in vitro assays, FOXM1 was overexpressed or knocked-down in benign (SF4433 and SF4068) or malignant (SF3061 and IOMM-Lee) humanmeningioma cell lines respectively. For in vivo studies, siomycin A (a FOXM1 inhibitor)-pretreated or control IOMM-Lee cells were implanted subcutaneously in nude mice. RESULTS:FOXM1 expression was increased in higher grades of meningioma and correlated with the mitotic index in the tumour tissue. Moreover, FOXM1 was increased in recurrent meningioma compared with the matched primary lesions. The patients who had higher FOXM1 expression had shorter PFS. In the subsequent in vitro assays, knockdown of FOXM1 in malignant meningioma cell lines resulted in decreased tumour cell proliferation, angiogenesis and invasion, potentially via regulation of β-catenin, cyclin D1, p21, interleukin-8, vascular endothelial growth factor-A, PLAU, and epithelial-to-mesenchymal transition-related genes, whereas overexpression of FOXM1 in benign meningioma cell lines had the opposite effects. Last, suppression of FOXM1 using a pharmacological inhibitor, siomycin A, decreased tumour growth in an in vivo mouse model. CONCLUSIONS: Our data demonstrate that FOXM1 is a key transcription factor regulating oncogenic signalling pathways in meningioma progression, and a promising therapeutic target for aggressive meningioma.
Authors: Niklas von Spreckelsen; Christoph Kesseler; Benjamin Brokinkel; Roland Goldbrunner; Arie Perry; Christian Mawrin Journal: Brain Pathol Date: 2022-03 Impact factor: 6.508
Authors: Jacob S Young; Reilly L Kidwell; Allison Zheng; Alex F Haddad; Manish K Aghi; David R Raleigh; Jessica D Schulte; Nicholas A Butowski Journal: Front Oncol Date: 2022-07-22 Impact factor: 5.738
Authors: William C Chen; Harish N Vasudevan; Abrar Choudhury; Melike Pekmezci; Calixto-Hope G Lucas; Joanna Phillips; Stephen T Magill; Matthew S Susko; Steve E Braunstein; Nancy Ann Oberheim Bush; Lauren Boreta; Jean L Nakamura; Javier E Villanueva-Meyer; Penny K Sneed; Arie Perry; Michael W McDermott; David A Solomon; Philip V Theodosopoulos; David R Raleigh Journal: Neurosurgery Date: 2020-12-15 Impact factor: 5.315